Targeted Therapy in Advanced Bladder Cancer What Have We Learned?

被引：13

作者：

Jordan, Emmet J. ^{[1
]}

Iyer, Gopa ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA

来源：

UROLOGIC CLINICS OF NORTH AMERICA | 2015年 / 42卷 / 02期

关键词：

Urothelial carcinoma; Targeted therapy; Small molecule inhibitors; Next-generation sequencing; Angiogenesis; MAPK pathway; PI3K/Akt/mTOR pathway; PHASE-II TRIAL; TRANSITIONAL-CELL CARCINOMA; EPIDERMAL-GROWTH-FACTOR; METASTATIC UROTHELIAL CARCINOMA; SUBEROYLANILIDE HYDROXAMIC ACID; HISTONE DEACETYLASE INHIBITOR; BEVACIZUMAB PLUS IRINOTECAN; DOUBLE-BLIND; COMPARING GEMCITABINE; 1ST-LINE TREATMENT;

D O I：

10.1016/j.ucl.2015.01.006

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Despite advances in the treatment of other genitourinary malignancies, no novel therapies have been approved by the US Food and Drug Administration for urothelial carcinoma (UC) in the last 20 years. To date, no clinical trials of targeted agents in UC have led to improvements in survival compared with cytotoxic therapy. This article outlines representative trials of targeted therapies in UC and discusses the significance of genetic preselection in trial design as a method to optimize responses to these agents, thus, hopefully expanding the armamentarium of treatment options against this lethal disease.

引用

页码：253 / +

页数：11

共 65 条

[1] EXPRESSION OF BASIC FIBROBLAST GROWTH-FACTOR AND ITS RECEPTOR IN AN INVASIVE BLADDER-CARCINOMA CELL-LINE [J].

ALLEN, LE ;

MAHER, PA .

JOURNAL OF CELLULAR PHYSIOLOGY, 1993, 155 (02) :368-375

[2]

Bakkar AA, 2003, CANCER RES, V63, P8108

[3] Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer [J].

Balar, Arjun V. ;

Apolo, Andrea B. ;

Ostrovnaya, Irina ;

Mironov, Svetlana ;

Iasonos, Alexia ;

Trout, Alisa ;

Regazzi, Ashley M. ;

Garcia-Grossman, Ilana R. ;

Gallagher, David J. ;

Milowsky, Matthew I. ;

Bajorin, Dean F. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06) :724-730

[4] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

[5] Novel approaches with targeted therapies in bladder cancer - Therapy of bladder cancer by blockade of the epidermal growth factor receptor family [J].

Bellmunt, J ;

Hussain, M ;

Dinney, CP .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 46 :S85-S104

[6] Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity [J].

Bellmunt, J. ;

Gonzalez-Larriba, J. L. ;

Prior, C. ;

Maroto, P. ;

Carles, J. ;

Castellano, D. ;

Mellado, B. ;

Gallardo, E. ;

Perez-Gracia, J. L. ;

Aguilar, G. ;

Villanueva, X. ;

Albanell, J. ;

Calvo, A. .

ANNALS OF ONCOLOGY, 2011, 22 (12) :2646-2653

[7] Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987 [J].

Bellmunt, Joaquim ;

von der Maase, Hans ;

Mead, Graham M. ;

Skoneczna, Iwona ;

De Santis, Maria ;

Daugaard, Gedske ;

Boehle, Andreas ;

Chevreau, Christine ;

Paz-Ares, Luis ;

Laufman, Leslie R. ;

Winquist, Eric ;

Raghavan, Derek ;

Marreaud, Sandrine ;

Collette, Sandra ;

Sylvester, Richard ;

de Wit, Ronald .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (10) :1107-1113

[8] Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens [J].

Bellmunt, Joaquim ;

Choueiri, Toni K. ;

Fougeray, Ronan ;

Schutz, Fabio A. B. ;

Salhi, Yacine ;

Winquist, Eric ;

Culine, Stephane ;

von der Maase, Hans ;

Vaughn, David J. ;

Rosenberg, Jonathan E. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) :1850-1855

[9] ANGIOGENESIS IN BLADDER-CANCER - RELATIONSHIP BETWEEN MICROVESSEL DENSITY AND TUMOR PROGNOSIS [J].

BOCHNER, BH ;

COTE, RJ ;

WEIDNER, N ;

GROSHEN, S ;

CHEN, SC ;

SKINNER, DG ;

NICHOLS, PW .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (21) :1603-1612

[10] Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer [J].

Choueiri, Toni K. ;

Ross, Robert W. ;

Jacobus, Susanna ;

Vaishampayan, Ulka ;

Yu, Evan Y. ;

Quinn, David I. ;

Hahn, Noah M. ;

Hutson, Thomas E. ;

Sonpavde, Guru ;

Morrissey, Stephanie C. ;

Buckle, Geoffrey C. ;

Kim, William Y. ;

Petrylak, Daniel P. ;

Ryan, Christopher W. ;

Eisenberger, Mario A. ;

Mortazavi, Amir ;

Bubley, Glenn J. ;

Taplin, Mary-Ellen ;

Rosenberg, Jonathan E. ;

Kantoff, Philip W. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05) :507-512

← 1 2 3 4 5 6 7 →